Dyslipidaemia in juvenile dermatomyositis: the role of disease activity

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorKOZU, K. T.
dc.contributor.authorSILVA, C. A.
dc.contributor.authorBONFA, E.
dc.contributor.authorSALLUM, A. M.
dc.contributor.authorPEREIRA, R. M. R.
dc.contributor.authorVIANA, V. S.
dc.contributor.authorBORBA, E.
dc.contributor.authorCAMPOS, L. M.
dc.date.accessioned2014-04-25T21:50:15Z
dc.date.available2014-04-25T21:50:15Z
dc.date.issued2013
dc.description.abstractObjective To evaluate the presence of dyslipidaemia in JDM and its possible risk factors. Methods Twenty-five JDM patients were compared to 25 healthy controls according to demographic data, body composition, fasting lipoproteins, glycaemia, insulin, antibodies and muscle enzymes. JDM scores were assessed: CMAS, MMT, DAS, MYOACT and MYTAX. Results Abnormal lipid profile was found in nine patients and four controls (36% vs. 16%, p=0.196). TDM patients demonstrated significant higher levels of triglycerides (TG) [80(31-340) vs. 61(19-182) mgldL, p=0.011 j and higher frequency of abnormal levels of high density lipoproteins (HDL) (28% vs. 4%, p=0.04) when compared to controls. JDM patients with dyslipidaemia demonstrated significant lower median of HDL levels 129(0-49) vs. 50(39-72) mgldL, p=0.0005, higher frequency of low HDL levels (77% vs. 0%, p=0.0001),.higher TG levels [128(31-340) vs. 69(46-138) mgldL, p=0.011), and also a higher frequency of increased levels of TG (44% vs. 0%, p=0.01), and TC (33% vs. 0%, p=0.03) when compared to those without this condition. Positive anti-LPL antibody was detected in just one JDM patient with abnormal lipid profile. JDM with dyslipidaemia had higher ESR (26 vs. I 4.5mmllsthour, p=0.006), CRP (2.1 vs. 0.4mgldL, p=0.01), DAS (6 vs. 2, p=0.008), MYOACT(0.13 vs. 0.01, p=0.012), MYTAX(0.06vs.0,p=0.018), and lower scores of CMAS (47 vs. 52, p=0.024) and MMT (78 vs. 80, p=0.001) compared to JDM without dyslipidaemia. Positive correlations were detected between TG levels and CRP (7-.19.697, p=0.001), DAS (r-0.610, p=0.001), MYOACT (r=0.661, p=0.001),114YTAX (r-0.511, p=0.008), and negative correlations with CMAS (r=-0.506, p=0.009) and MMT (r=-0.535, p=0.005). No differences were found between these groups regarding body composition, lipodystrophy, anti-LPL antibodies, and treatment except by higher frequency of cyclosporine current use in patients with dys.lipidaemia (33% vs. 0%, p=0.03). Conclusions Dyslipidaemia in JDM patients was characterised by increased levels of TG and low levels of HDL. Disease activity and cyclosporine use were the mainly factors associated to these abnormalities.
dc.description.indexMEDLINE
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Selo Paulo FAPESP [08158238-4]
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPQ [30272412011-7, 30055912009-7, 30696312011-6]
dc.description.sponsorshipFederico Foundation
dc.identifier.citationCLINICAL AND EXPERIMENTAL RHEUMATOLOGY, v.31, n.4, p.638-644, 2013
dc.identifier.issn0392-856X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/5064
dc.language.isoeng
dc.publisherCLINICAL & EXPER RHEUMATOLOGY
dc.relation.ispartofClinical and Experimental Rheumatology
dc.rightsrestrictedAccess
dc.rights.holderCopyright CLINICAL & EXPER RHEUMATOLOGY
dc.subjectdyslipidaemia
dc.subjectjuvenile dermatomyositis
dc.subjectautoantibody
dc.subjecteyelosporine
dc.subjectdisease activity
dc.subject.othersystemic-lupus-erythematosus
dc.subject.otherdensity-lipoprotein cholesterol
dc.subject.othercardiovascular risk profile
dc.subject.otheridiopathic arthritis
dc.subject.otherchildren
dc.subject.othertherapy
dc.subject.otherhypercholesterolemia
dc.subject.otherlipodystrophy
dc.subject.otherreliability
dc.subject.othervalidity
dc.subject.wosRheumatology
dc.titleDyslipidaemia in juvenile dermatomyositis: the role of disease activity
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus22
hcfmusp.contributor.author-fmusphcKATIA TOMIE KOZU
hcfmusp.contributor.author-fmusphcCLOVIS ARTUR ALMEIDA DA SILVA
hcfmusp.contributor.author-fmusphcELOISA SILVA DUTRA DE OLIVEIRA BONFA
hcfmusp.contributor.author-fmusphcADRIANA MALUF ELIAS SALLUM
hcfmusp.contributor.author-fmusphcROSA MARIA RODRIGUES PEREIRA
hcfmusp.contributor.author-fmusphcVILMA DOS SANTOS TRINDADE VIANA
hcfmusp.contributor.author-fmusphcEDUARDO FERREIRA BORBA NETO
hcfmusp.contributor.author-fmusphcLUCIA MARIA MATTEI DE ARRUDA CAMPOS
hcfmusp.description.beginpage638
hcfmusp.description.endpage644
hcfmusp.description.issue4
hcfmusp.description.volume31
hcfmusp.origemWOS
hcfmusp.origem.pubmed23557696
hcfmusp.origem.scopus2-s2.0-84883546439
hcfmusp.origem.wosWOS:000330326800023
hcfmusp.publisher.cityPISA
hcfmusp.publisher.countryITALY
hcfmusp.relation.referenceArdoin SP, 2010, LUPUS, V19, P1315, DOI 10.1177/0961203310373937
hcfmusp.relation.referenceBALLANTYNE CM, 1989, JAMA-J AM MED ASSOC, V262, P53, DOI 10.1001/jama.262.1.53
hcfmusp.relation.referenceBingham A, 2008, MEDICINE, V87, P70, DOI 10.1097/MD.0b013e31816bc604
hcfmusp.relation.referenceBode RK, 2003, ARTHRIT RHEUM-ARTHR, V49, P7, DOI 10.1002/art.10924
hcfmusp.relation.referenceBOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
hcfmusp.relation.referenceBorba EF, 2001, J RHEUMATOL, V28, P780
hcfmusp.relation.referenceBorba EF, 2006, CLIN DEV IMMUNOL, V13, P203, DOI 10.1080/17402520600876945
hcfmusp.relation.referenceCarreau V, 2011, PEDIATR DRUGS, V13, P267, DOI 10.2165/11591650-000000000-00000
hcfmusp.relation.referenceCoyle Kathleen, 2009, J Pediatr, V155, P882, DOI 10.1016/j.jpeds.2009.06.009
hcfmusp.relation.referencede Carvalho JF, 2004, ARTHRITIS RHEUM, V50, P3610, DOI 10.1002/art.20630
hcfmusp.relation.referenceEimer MJ, 2011, J PEDIATR-US, V159, P795, DOI 10.1016/j.jpeds.2011.05.015
hcfmusp.relation.referenceFOSSATI P, 1982, CLIN CHEM, V28, P2077
hcfmusp.relation.referenceFRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
hcfmusp.relation.referenceHayata ALS, 2005, LUPUS, V14, P613, DOI 10.1191/0961203305lu2177oa
hcfmusp.relation.referenceHuemer C, 2001, J RHEUMATOL, V28, P610
hcfmusp.relation.referenceKROLL M, 1986, J RHEUMATOL, V13, P349
hcfmusp.relation.referenceLovell DJ, 1999, ARTHRITIS RHEUM, V42, P2213, DOI 10.1002/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8
hcfmusp.relation.referenceMarangoni RG, 2011, CLINICS, V66, P1549, DOI 10.1590/S1807-59322011000900007
hcfmusp.relation.referenceMarcen R, 2006, TRANSPLANT P, V38, P2427, DOI 10.1016/j.transproceed.2006.08.070
hcfmusp.relation.referenceMiller LW, 2002, AM J TRANSPLANT, V2, P807, DOI 10.1034/j.1600-6143.2002.20902.x
hcfmusp.relation.referenceOmori CH, 2012, ARTHRIT CARE RES, V64, P1186, DOI 10.1002/acr.21684
hcfmusp.relation.referencePEREIRA A, 2005, ARQ BRAS CARDIOL, V8, P4
hcfmusp.relation.referencePosadas-Romero C, 2004, ARTHRITIS RHEUM, V50, P160, DOI 10.1002/art.11472
hcfmusp.relation.referencePRADO R, 2006, CLIN EXP RHEUMATOL, V24, P594
hcfmusp.relation.referenceSallum AME, 2002, ARQ NEURO-PSIQUIAT, V60, P889, DOI 10.1590/S0004-282X2002000600001
hcfmusp.relation.referenceSarkissian T, 2006, ARTHRITIS RHEUM, V54, P1283, DOI 10.1002/art.21748
hcfmusp.relation.referenceSato JO, 2009, CLIN EXP RHEUMATOL, V27, P1031
hcfmusp.relation.referenceSchanberg LE, 2012, ARTHRITIS RHEUM-US, V64, P285, DOI 10.1002/art.30645
hcfmusp.relation.referenceSIEDEL J, 1983, CLIN CHEM, V29, P1075
hcfmusp.relation.referenceSultan SM, 2008, ARTHRITIS RHEUM, V58, P3593, DOI 10.1002/art.23963
hcfmusp.relation.referenceTargoff Ira N, 2002, Curr Rheumatol Rep, V4, P434, DOI 10.1007/s11926-002-0089-7
hcfmusp.relation.referenceVerma S, 2006, ARTHRIT RHEUM-ARTHR, V55, P564, DOI 10.1002/art.22108
hcfmusp.relation.referenceWARNICK GR, 1979, CLIN CHEM, V25, P596
hcfmusp.relation.referenceZanette CD, 2010, REV BRAS REUMATOL, V50, P190, DOI 10.1590/S0482-50042010000200008
hcfmusp.remissive.sponsorshipCNPq
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.remissive.sponsorshipFederico Foundation
hcfmusp.remissive.sponsorshipCNPq
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.remissive.sponsorshipFederico Foundation
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication9a61ce49-e3bb-42bd-b971-559009658a3c
relation.isAuthorOfPublication6c3c5459-9dbb-4a5c-98b1-d7b76943b87d
relation.isAuthorOfPublication708e64de-56af-4523-b920-b237f71535b2
relation.isAuthorOfPublicationf4a01210-82ac-45c8-a5d6-62dc15444465
relation.isAuthorOfPublicationa7d269ab-50f5-415f-a84f-b03f05f2093c
relation.isAuthorOfPublication798a3a64-2f34-43cc-8607-d79c1f218edd
relation.isAuthorOfPublicationff552d3d-2962-42d9-a9f3-99f3990380fa
relation.isAuthorOfPublication56623da9-adae-4ac2-99f9-75fd739393a9
relation.isAuthorOfPublication.latestForDiscovery9a61ce49-e3bb-42bd-b971-559009658a3c
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36